KANSERLİ GENEL CERRAHİ HASTALARININ 2018-2019-2020 YILI ÖZÜRLÜ HEYET VERİLERİ

Günay Uluç

doi:10.18614/deutip.1275211

Research Article

GENERAL SURGERY CANCER PATİENTS' 2018-2019-2020 HEALTH BOARD DATA

Year 2023, Volume: 37 Issue: 3, 259 - 271, 25.01.2024

Günay Uluç

https://doi.org/10.18614/deutip.1275211

Abstract

ABSTRACT:
To prevent socioeconomic losses, many adults in our country apply to “Disability Health Boards” after the recipient of a cancer diagnose as it pertains to general surgery. These applicants acquire health board report consisting of a disability percentage that is determined in accord with the “Regulation on Classification of Disability Criteria and Health Board Reports to be Given to People with Disabilities.” In this respect, our study assesses the results of the applications filed by cancer patients with the Disability Health Board of the IMU Süleyman Yalçın Şehir Hospital General Surgery in 2018-2019-2020.

Keywords

CANCER, HEALTH BOARD, PHYSİCAL İNTEGRİTY, SOCİAL LOSS

Project Number

YOK

References

1. Kanser hastalarına yönelik sosyal hizmetler ve sosyal güvenlik düzenlemeleri. Oğuzhan Zengin, Barış Öztuna Ufkun Ötesi Bilim Dergisi Cilt 18.Sayı1. 2018
2. Türkiye Halk Sağlığı Kurumu Kanser Daire Başkanlığı 2016.Türkiye Kanser istatistikleri Raporu.26 mart 2017.http://kanser.gov.tr/dosya/ca.istatistik/ Türkiye Kanser
3. Devlet İstatistik Enstitüsü. DİE. Türkiye Özürlüler Araştırması 2002. DİE Matbaası Ankara 2004
4. Göztepe Eğitim ve Araştırma Hastanesi Özürlü Çocuk Heyetinin 2010 Yılı Verileri. Şaziye Sanem Başgül, Sema Saltık Göztepe tıp dergisi 27.(2)-20125)
5. The European ancer Cancer Patıents Bıll Of Rights Update and Implementatıon 2016.EMO open 2016.Lawler M et all.
6. Türkiye’de kanserin ekonomik maliyetleri: Bir hesaplanabilir genel denge modeli yaklaşımı Pınar Torun, Aziz Kutlar. Hacettepe Sağlık İdaresi Dergisi 2018:21 (1)
7. Economic Burden of Cancer in the Unıted States: Estımates Projectıons and Future Research. : Yabroff K.,Lund J., Kepka D.,Marıottİ A. Cancer Epidemıol, Bıomarkers: (2011 - 20(10):2006-2014
8. Avrupa’da Kanserin Maliyeti. (The cost of cancer ın Europe) 2018. Thomas Hofmarcher, Peter Lindgren, Nils Wilking, Bengt Jönnson.European Journal of Cancer 2020 129:41-49)
9. Resmi Gazete.12 Haziran 2002. Özel tüketim vergisi kanunu.
10. Erken mide kanserinin endoskopik tedavisi bugünkü durum ve gelecek (Endoscopic treatment of superficial gastric cancer: present status and future). Hiruyuki Hisadasi et all. CURRENT ONCOLOGY2022 Special Issues
11. Globocan Cancer Statıstıcs. Hjuna Song,Jacques Ferlay,R.L. Siegel, Mathiew Lawersanne, Soerjomataram İsabella, Bray Freddıe, Ahmedin Cemal.. ACS JOURNAL for CLİNİCİANS. Volume71 (3) 2021 may 12. Breast Cancer Vaccınes Disappoınting or Promising ?. Si Yuan Zhu, Ke Da Yu, Frontiers in Immunology 2022:VOLUM: 1: 828386
13. Breast Cancer Vaccınes for Treatment and Preventıon .ML Disis,Denise L. Cecil. Breast Cancer Research and Treatment 191.30 november 2021. 14. Clinical Development of the E-75 Vaccine in Breast Cancer. Breast Care 2016:11 Guy T.Clifton et all.
15. Therapeutic Vaccines For Breast Cancer: Has the time finally come ?.European Journal of Cancer 160 (2022) Chiara Cortıc et all.
16. Immunotherapy for HER 2 positive Breast Cancer: Clinical evidence and future perspectives. Elisa Agostinetto, Filippo Montemurro,Alberto Zambelli,et all. Cancers 2022-14-2136.
17. Immunotherapies against HER-2 positive breast cancer: Santıago Duro Sanchez, Macerana Roman Alonso, Joaquın Aribas. Cancers 2023,15,1069.
18. HER-2 positive Breast Cancer Immunotherapy: A focus on vaccine development. Atefeh Arab, Rezvan Yazdian Robati, Javad Bahravan. Arch ımmunol ther exp. 2020.
19. Kanser kaydının önemi ve Kanser kontrolündeki yeri. Mehmet Emin Arayıcı, Femin Yalçın, Hülya Ellidokuz. STED 2021.30 (5) 20. Kanun Teklifi. İzzet Ulvi Yönter. Türkiye Büyük Millet Meclisi 28. dönem Milletvekili.